Sweden's BioGaia Q3 sales rise on pediatrics and adult health segments 

Overview

• Sweden probiotic products maker's Q3 net sales rose 23% yr/yr excluding currency effects

• Adjusted EPS for Q3 increased yr/yr

• Growth driven by both Pediatrics and Adult Health segments across key markets

Outlook

• Company says it will focus on growth and profitability in the final quarter

• BioGaia plans continued investment in science-based innovation and market expansion

• Company to roll out new Colus product in UK, with phased launch in other markets

Result Drivers

• MARKETING AND DISTRIBUTION - Increased consumer and medical marketing in the Americas and expanded distribution in EMEA contributed to sales growth

• ADULT HEALTH SEGMENT - Strong sales growth in Adult Health segment, especially for Prodentis product

• ORDER TIMING - EMEA sales benefited from orders shifted forward from Q4

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Biogaia AB is SEK160.00, about 29% above its October 21 closing price of SEK124.00

• The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 27 three months ago

Reuters Recommended Reads

• Oct 22 - Sweden's Sedana Medical Q3 sales rise as growth returns

• Oct 22 - Sweden's Careium Q3 sales rise 21.6%, margin improves

• Oct 22 - Sweden's Bactiguard Q3 revenue rises on partnership with Becton, Dickinson & Company

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)